Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low105.10 28/06/17
52 week change -30.25 (-20.34%)
4 week volume684,883 25/06/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona nears Phase 2b clinical trial for RPL554

Verona Pharma announces regulatory approval in five European countries for a Phase 2b dose-ranging trial of RPL554 fo...

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

Miscellaneous medium priority announcements

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs

Miscellaneous medium priority announcements

Verona Pharma plc : Holding(s) in Company

Notification of major interests in shares

Verona Pharma plc : Holding(s) in Company

Notification of major interests in shares

Verona initiates US clinical pharmacokinetic study for RPL554

Verona Pharma has announced the initiation of a clinical pharmacokinetic trial in the US for its product candidate RPL55...

Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA

Miscellaneous medium priority announcements

Verona CEO to present at Jefferies Healthcare Conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the Jeffer...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: Directors Pay

    Taken years already and if they want that sort of pay it wont belong before you can divide the share price by 10 again..
    19-Jun-2017
    Philbot44
  • Re: Directors Pay

    Hi Raptor & MOL, Full credit to you guys for 'Holding On' in VRP, (Rap I guess you meant email VRP not N?). I held these shares for about a year and sold out when VRP ...
    19-Jun-2017
    lawrence77
  • Re: Directors Pay

    I emailed VRP asking them to explain the high salary, I got a reply but no mention of the CEO salary. I have emailed VRN again ~4weeks ago, with no reply to the date. If ...
    19-Jun-2017
    raptor66

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.21%
RENEURON11%
BP10%
GULF KEYSTONE10%
RANGE RES.10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP